The advent of precision oncology has transformed cancer care. Yet only approximately 25% of patients are eligible for targeted therapies, as current approaches exploit tumors harboring well-characterized somatic driver alterations. This limitation has restricted the broader clinical impact of precision medicine and c...
Nicole Peiris, Sean A. Misek, Angela Chen et al.· Cancer Epidemiology, Biomark...· 0 citations
Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have large...
Anna Borgenvik, Sean A. Misek, Daniel Christen et al.· bioRxiv· 1 citation
These intrinsic posttranslational modifications of the KIAA1549 ectodomain are critical determinants of the cellular trafficking that lead to activation of the BRAF oncogene, potentially involving a cascade of cleavage events in the Golgi that ultimately release a truncated but fully active BRAF kinase domain into the...
Gloria Kyrila, Serpil Ahmed, Anna Borgenvik et al.· Journal of Biological Chemis...· 0 citations
A large-scale international programme—the Human Cancer Models Initiative—is presented, which involved the generation of a resource of 665 next-generation models from 2,780 donors with 25 cancer types and integrated tumour–model whole genome, exome, methylome and transcriptome analyses.
Dina Elharouni, Mushriq Al-Jazrawe, Seongmin Choi et al.· Nature· 7 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.